FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080640948> ?p ?o ?g. }

• W3080640948 endingPage "274" @default.
• W3080640948 startingPage "267" @default.
• W3080640948 abstract "Abstract Background Despite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated. Methods From a pooled cohort of four observational studies, we selected CKD patients receiving short-acting (epoetin α/β; n = 299) or long-acting ESAs (darbepoetin and methoxy polyethylene glycol-epoetin β; n = 403). The primary composite endpoint was end-stage kidney disease (ESKD; dialysis or transplantation) or all-cause death. Multivariable Cox models were used to estimate the relative risk of the primary endpoint between short- and long-acting ESA users. Results During follow-up [median 3.6 years (interquartile range 2.1–6.3)], the primary endpoint was registered in 401 patients [166 (72%) in the short-acting ESA group and 235 (58%) in the long-acting ESA group]. In the highest tertile of short-acting ESA dose, the adjusted risk of primary endpoint was 2-fold higher {hazard ratio [HR] 2.07 [95% confidence interval (CI) 1.37–3.12]} than in the lowest tertile, whereas it did not change across tertiles of dose for long-acting ESA patients. Furthermore, the comparison of ESA type in each tertile of ESA dose disclosed a significant difference only in the highest tertile, where the risk of the primary endpoint was significantly higher in patients receiving short-acting ESAs [HR 1.56 (95% CI 1.09–2.24); P = 0.016]. Results were confirmed when ESA dose was analysed as continuous variable with a significant difference in the primary endpoint between short- and long-acting ESAs for doses &gt;105 IU/kg/week. Conclusions Among non-dialysis CKD patients, the use of a short-acting ESA may be associated with an increased risk of ESKD or death versus long-acting ESAs when higher ESA doses are prescribed." @default.
• W3080640948 created "2020-09-01" @default.
• W3080640948 creator A5000184049 @default.
• W3080640948 creator A5004472342 @default.
• W3080640948 creator A5005736449 @default.
• W3080640948 creator A5010126422 @default.
• W3080640948 creator A5022470178 @default.
• W3080640948 creator A5048229494 @default.
• W3080640948 creator A5071768099 @default.
• W3080640948 creator A5080793108 @default.
• W3080640948 date "2020-08-23" @default.
• W3080640948 modified "2023-09-30" @default.
• W3080640948 title "Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease" @default.
• W3080640948 cites W1564884763 @default.
• W3080640948 cites W1971734795 @default.
• W3080640948 cites W1981510651 @default.
• W3080640948 cites W1994505918 @default.
• W3080640948 cites W1996285359 @default.
• W3080640948 cites W1998943227 @default.
• W3080640948 cites W2005973637 @default.
• W3080640948 cites W2009143579 @default.
• W3080640948 cites W2016532897 @default.
• W3080640948 cites W2026452824 @default.
• W3080640948 cites W2026716582 @default.
• W3080640948 cites W2031196132 @default.
• W3080640948 cites W2037062476 @default.
• W3080640948 cites W2040029744 @default.
• W3080640948 cites W2046084295 @default.
• W3080640948 cites W2046224330 @default.
• W3080640948 cites W2049258517 @default.
• W3080640948 cites W2066074182 @default.
• W3080640948 cites W2072318332 @default.
• W3080640948 cites W2087773817 @default.
• W3080640948 cites W2089791455 @default.
• W3080640948 cites W2095421717 @default.
• W3080640948 cites W2106114378 @default.
• W3080640948 cites W2106959466 @default.
• W3080640948 cites W2113512403 @default.
• W3080640948 cites W2113559481 @default.
• W3080640948 cites W2131475963 @default.
• W3080640948 cites W2134389978 @default.
• W3080640948 cites W2134487085 @default.
• W3080640948 cites W2148520689 @default.
• W3080640948 cites W2151511116 @default.
• W3080640948 cites W2152575253 @default.
• W3080640948 cites W2152811977 @default.
• W3080640948 cites W2158383145 @default.
• W3080640948 cites W2159106432 @default.
• W3080640948 cites W2161519672 @default.
• W3080640948 cites W2165609257 @default.
• W3080640948 cites W2170328739 @default.
• W3080640948 cites W2527972208 @default.
• W3080640948 cites W2683951606 @default.
• W3080640948 cites W2767839794 @default.
• W3080640948 cites W2941651537 @default.
• W3080640948 cites W2966965512 @default.
• W3080640948 cites W2969121196 @default.
• W3080640948 cites W3149132779 @default.
• W3080640948 doi "https://doi.org/10.1093/ndt/gfaa088" @default.
• W3080640948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32829405" @default.
• W3080640948 hasPublicationYear "2020" @default.
• W3080640948 type Work @default.
• W3080640948 sameAs 3080640948 @default.
• W3080640948 citedByCount "9" @default.
• W3080640948 countsByYear W30806409482020 @default.
• W3080640948 countsByYear W30806409482021 @default.
• W3080640948 countsByYear W30806409482022 @default.
• W3080640948 countsByYear W30806409482023 @default.
• W3080640948 crossrefType "journal-article" @default.
• W3080640948 hasAuthorship W3080640948A5000184049 @default.
• W3080640948 hasAuthorship W3080640948A5004472342 @default.
• W3080640948 hasAuthorship W3080640948A5005736449 @default.
• W3080640948 hasAuthorship W3080640948A5010126422 @default.
• W3080640948 hasAuthorship W3080640948A5022470178 @default.
• W3080640948 hasAuthorship W3080640948A5048229494 @default.
• W3080640948 hasAuthorship W3080640948A5071768099 @default.
• W3080640948 hasAuthorship W3080640948A5080793108 @default.
• W3080640948 hasConcept C119060515 @default.
• W3080640948 hasConcept C126322002 @default.
• W3080640948 hasConcept C168563851 @default.
• W3080640948 hasConcept C203092338 @default.
• W3080640948 hasConcept C207103383 @default.
• W3080640948 hasConcept C2778063415 @default.
• W3080640948 hasConcept C2778653478 @default.
• W3080640948 hasConcept C2779978075 @default.
• W3080640948 hasConcept C2780303639 @default.
• W3080640948 hasConcept C2781404941 @default.
• W3080640948 hasConcept C2911091166 @default.
• W3080640948 hasConcept C44249647 @default.
• W3080640948 hasConcept C50382708 @default.
• W3080640948 hasConcept C71924100 @default.
• W3080640948 hasConceptScore W3080640948C119060515 @default.
• W3080640948 hasConceptScore W3080640948C126322002 @default.
• W3080640948 hasConceptScore W3080640948C168563851 @default.
• W3080640948 hasConceptScore W3080640948C203092338 @default.
• W3080640948 hasConceptScore W3080640948C207103383 @default.
• W3080640948 hasConceptScore W3080640948C2778063415 @default.
• W3080640948 hasConceptScore W3080640948C2778653478 @default.

• next